Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Updates in atypical hemolytic syndrome.
Curr Opin Pediatr
January 2025
Division of Pediatric Nephrology, The University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Purpose Of Review: This review aims to summarize how scientific advances in complement biology have not only improved the diagnosis and management of aHUS but also continue to offer insights into the pathophysiology of complement-mediated disease that may be leveraged for future therapeutic developments.
Recent Findings: Updated information on the clinical and epidemiological features, pathophysiology, diagnosis, management, and potential for future therapeutic advancements in the treatment of aHUS are reviewed.
Summary: aHUS is a rare but potentially life-threatening disease that requires prompt diagnosis and treatment as well as long-term management via a multidisciplinary team providing coordination of primary and specialty care as well as outreach and education for children and families affected by this life-long disease.
Steroid-resistant nephrotic syndrome due to renal-limited thrombotic microangiopathy and membranous nephropathy after allogeneic hematopoietic stem cell transplantation successfully treated with calcineurin inhibitors.
Int J Hematol
January 2025
Department of Hematology, Kobe City Medical Center General Hospital, 2-1-1, Minatojima-Minamimachi, Chuo-ku, Kobe, 650-0047, Japan.
Transplantation-associated thrombotic microangiopathy (TMA) is a severe complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT) with high mortality. As calcineurin inhibitors (CNIs) reportedly contribute to TMA via drug-induced endothelial injury, treatment of TMA often involves CNI discontinuation or dose reduction. However, renal-limited TMA, defined as biopsy-proven renal TMA without the classical triad (hemolytic anemia, thrombocytopenia, and organ damage), has rarely been reported after allo-HSCT, and its optimal management remains unknown.
View Article and Find Full Text PDFMitapivat: a step forward across different hemolytic diseases.
Expert Opin Emerg Drugs
January 2025
Division of Hematology & Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
Abdominal Aortic Aneurysm with Primary Cold Agglutinin Disease Treated with Endovascular Aortic Repair.
Ann Vasc Dis
January 2025
Department of Surgery, Hiroshima Red Cross Hospital and Atomic-bomb Survivors Hospital, Hiroshima, Hiroshima, Japan.
Cold agglutinin disease (CAD) is a rare and autoimmune hemolytic disorder caused by the presence of cold-reacting autoantibodies against red blood cells. An abdominal aortic aneurysm (AAA) is a potentially life-threatening condition. This report describes an 83-year-old man with AAA who was diagnosed with primary CAD 9 years before undergoing AAA surgery.
View Article and Find Full Text PDFDetection of Mycoplasma haemocanis and Candidatus Mycoplasma haematoparvum in shelter and pet dogs in Malaysia.
Trop Biomed
December 2024
Department of Veterinary Pathology & Microbiology, Faculty of Veterinary Medicine, Universiti Putra Malaysia, Serdang, Malaysia.
Canine haemotrophic mycoplasmosis is caused by mycoplasma haemopathogens, which includes Mycoplasma haemocanis (Mhc) and Candidatus Mycoplasma haematoparvum (CMhp). The Mhc and CMhp pose a health risk to dogs, particularly in immunocompromised and splenectomised dogs, as they lead to haemolytic anaemia. There is scarce information on the detection of Mycoplasma in dogs in Malaysia.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!